ulixacaltamide

Praxis Shares Fall 48% Following Mixed Data for Essential Tremor Candidate
BioSpace
Mon, 03/6/23 - 11:13 am
Praxis Precision Medicines
ulixacaltamide
clinical trials
essential tremor
Praxis share price halved after essential tremor fail, but biotech still plans phase 3
Fierce Biotech
Fri, 03/3/23 - 10:04 am
Praxis Precision Medicines
clinical trials
essential tremors
ulixacaltamide